TABLE 8 Incidence of Malaria During Prophylactic Effect 1 (Period of 35 Days After Dose at 3 Months)

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Placebo

Episodes

10

45

41

44

5

17

PYAR

30

98

55

48

48

53

Incidence

0.33

0.46

0.75

0.92

0.10

0.32

IPTi with SP

Episodes

2

10

17

8

2

6

PYAR

30

98

57

49

48

55

Incidence

0.07

0.10

0.30

0.16

0.04

0.11

Efficacy (95% CI)

80 (9, 96)

78 (52, 90)

60 (29, 77)

82 (62, 92)

75 (−240, 98)

83 (13, 97)

p-value

0.038

<0.001

0.002

<0.001

0.29

0.034

NOTE: PYAR: Person-years at risk.

SOURCE: Reprinted with permission from the Statistical Working Group (IPTi Consortium, 2007b).

TABLE 9 Incidence of Malaria During Prophylactic Effect 2 (Period of 35 Days After Dose at 9 Months)

Location, Country

Ifakara, Tanzania

Navrongo, Ghana

Manhiça, Mozambique

Kumasi, Ghana

Lambaréné, Gabon

Tamale, Ghana

Placebo

Episodes

23

147

33

53

10

30

PYAR

25

107

49

40

40

51

Incidence

0.92

1.4

0.67

1.3

0.25

0.58

IPTi with SP

Episodes

2

33

10

25

6

5

PYAR

26

107

51

41

40

53

Incidence

0.08

0.31

0.20

0.61

0.15

0.09

Efficacy (95% CI)

92 (64, 98)

78 (67, 84)

71 (41, 86)

54 (27, 72)

42 (−78, 82)

96 (85, 99)

p-value

0.001

<0.001

0.001

0.001

0.34

<0.001

NOTE: PYAR: Person-years at risk.

SOURCE: Reprinted with permission from the Statistical Working Group (IPTi Consortium, 2007b).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement